Clemann Group

Clemann Group is a private French life sciences services company that provides strategic and operational support for pharmaceutical and medical device development. The company positions itself as a multidisciplinary platform integrating industrial affairs, CMC, regulatory strategy, preclinical and clinical development, intellectual property, licensing, and legal representation for clinical research in the EU. It appears to primarily serve innovators, start-ups, and developers in pharma, biotech, and medtech rather than operate as a traditional therapeutics company. In addition to its services business, recent disclosures indicate it has developed blood-brain barrier delivery technology and central nervous system Alzheimer's-related assets that were the subject of a March 26, 2026 binding acquisition agreement with Lunai Bioworks. Overall, Clemann Group is best characterized as a health-focused pharmaceutical development services platform with at least one disclosed CNS/BBB-related internal asset set.